Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Detalles Bibliográficos
Autores principales: Ament, Michael, Day, Kathleen, Stauffer, Virginia L., Skljarevski, Vladimir, Rettiganti, Mallikarjuna, Pearlman, Eric, Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393809/
https://www.ncbi.nlm.nih.gov/pubmed/34445967
http://dx.doi.org/10.1186/s10194-021-01307-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393809/
https://www.ncbi.nlm.nih.gov/pubmed/34445967
http://dx.doi.org/10.1186/s10194-021-01307-6

Ejemplares similares